The Foundation for the National Institute of Health in the US selects Clear Cell Sarcoma to focus its research efforts on

In late September 2025 the Foundation for the National Institute of Health (FNIH) in the US, announced its ULTRA Programme had selected Clear Cell Sarcoma, from over 250 rare cancers, to focus their future research efforts upon.

The FNIH seeks to form public-private partnerships to accelerate biomedical research and has raised over $1.5 billion dollars since it was founded in 1990.

Clear Cell Sarcoma was selected because it was considered to have a mutation that is targetable and, due to the limited
number of patients affected, it is unlikely pharmaceutical companies will specifically invest to find a cure.

The involvement of the FNIH could help to leverage investment into research into Clear Cell Sarcoma and is therefore a potentially massive boost to finding a cure for this terrible disease.
The FNIH is held a meeting in Washington DC on the 22nd and 23rd January 2026, with a view to commence the process of preparing a roadmap for future research.

Having already produced such a plan, we are very aware of the potential this represents to hopefully form collaborations with institutes in the US.

Dr Priya Chadasama represented our consortium and made an excellent online presentation of our roadmap and outlined how we saw the future directions of research.